Objective. To evaluate the role of second-look laparotomy following pl
atinum-based chemotherapy in patients with fallopian tube cancer. Meth
ods: We conducted a retrospective chart review of 35 patients with tub
al cancer who underwent a second-look laparotomy following cytoreducti
ve surgery and platinum-based combination chemotherapy. Results: The d
istribution by stage was as follows: 1, three (9%); II, five (14%); II
I, 24 (69%); and IV, two (6%); one patient was inadequately staged. Th
e tumor grade was recorded in 31 patients, and 80% of these were grade
2 or 3. Twenty-one of the 35 patients (60%) were found to be free of
disease at second-look operation. Neither stage nor grade were predict
ive of findings at the second-look procedure, although none of the fiv
e patients with stage I disease and/or grade 1 tumor had disease found
at second-look surgery. The absence of gross residual disease followi
ng primary surgery was the strongest predictor of disease-free status
at second-look laparotomy (P < .01). With a mean follow-up of 50 month
s among the survivors, only four (19%) of the patients with no evidenc
e of tumor at reexploration have had a recurrence. Conclusion: Second-
look laparotomy provides useful prognostic information in patients wit
h tubal cancer, approximately 80% of patients who have a negative seco
nd-look following platinum-based chemotherapy will remain disease-free
.